Company intelligence / Profile preview

Endogun Medical Systems

Ownership: Private
Development stage: Other

Overview

Endogun Medical Systems developed the EndoFast Reliant system for minimally invasive pelvic organ prolapse repair. The system aimed to reduce the invasiveness of traditional multi-incision procedures. The company received regulatory approvals and launched initial clinical studies. In early 2010, it announced plans to change its name to Israel Biomedical Innovations and expand through acquisitions[3].

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Endogun Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogun Medical Systems.

Explore the full profile